H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases

Altimmune, Inc. (NASDAQ:ALT) earns a spot on our list of the top 10 stocks under $5 that could triple.

On March 16, 2026, H.C. Wainwright noted growing optimism around pipeline expansion and upside potential by raising the price target for Altimmune, Inc. (NASDAQ:ALT) from $12 to $25, while maintaining a “Buy” rating on the stock. Altimmune, Inc. (NASDAQ:ALT)’s strategic focus on its MASH program has strengthened the investment narrative amid growing attention toward treatments for metabolic and liver diseases.

H.C. Wainwright analysts highlighted Altimmune, Inc. (NASDAQ:ALT)’s focus on its intended MASH pivotal program, while also incorporating additional value from pemvidutide in alcohol-related liver disease and alcohol use disorder into their model. Significant unmet need and promising clinical and preclinical liver results were identified by the firm as key drivers.

Meanwhile, Pemvidutide’s differentiation as it enters Phase 3 trials, the upcoming Phase 2 RECLAIM AUD topline data in Q3 2026, and a $340 million pro-forma cash runway are factors bolstering the company’s outlook, according to analysts at B. Riley, who, on March 6, 2026, lowered the firm’s price target to $13 from $18 while maintaining a “Buy” rating.

Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biopharmaceutical company engaged in developing peptide-based therapeutics, such as pemvidutide for obesity and NASH, and HepTcell, an immunotherapy designed to achieve a functional cure for hepatitis B.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.